EGFR and neoplasm: In the course of her disease, resistance alteration became undetectable, and the tumor was successfully rechallenged with the original first-generation <i>EGFR</i> TKI as well as osimertinib and altogether showed prolonged response despite a prognostically negative <i>TP53</i> alteration.